» Articles » PMID: 20093909

Daily Compared with 8-hour Gentamicin for the Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial

Overview
Journal Obstet Gynecol
Date 2010 Jan 23
PMID 20093909
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess whether daily gentamicin is as effective as 8-hour gentamicin for the treatment of intrapartum chorioamnionitis.

Methods: Women with a clinical diagnosis of chorioamnionitis between 32 and 42 weeks of gestation were randomly assigned in labor to receive either daily gentamicin (5 mg/kg intravenously (IV), then 2 placebo doses IV after 8 and 16 hours) or 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours). Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses). Patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses). The primary outcome was treatment success, defined by resolution of chorioamnionitis after 16 hours of treatment without development of endometritis. One hundred twenty-six patients were required to have 95% confidence that daily gentamicin is at worst 15% inferior to 8-hour dosing with an alpha of .05 and a beta of 0.2.

Results: One hundred twenty-six women were enrolled, of whom 63 received daily gentamicin and 63 received 8-hour gentamicin. One patient was excluded from data analysis. Baseline maternal and obstetric characteristics were similar between groups except for longer mean duration of ruptured membranes in the 8-hour group (679+/-514 compared with 469+/-319 minutes; P =.03). Treatment success was equal between groups (94% daily gentamicin compared with 89% 8-hour gentamicin, P =.53). There were no differences in maternal or neonatal morbidities, including neonatal sepsis and newborn hearing screen.

Conclusion: Daily and 8-hour gentamicin appear equally effective for the treatment of intrapartum chorioamnionitis.

Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00185991.

Level Of Evidence: I.

Citing Articles

Clinical chorioamnionitis at term: definition, pathogenesis, microbiology, diagnosis, and treatment.

Jung E, Romero R, Suksai M, Gotsch F, Chaemsaithong P, Erez O Am J Obstet Gynecol. 2024; 230(3S):S807-S840.

PMID: 38233317 PMC: 11288098. DOI: 10.1016/j.ajog.2023.02.002.


Neonatal Serum Gentamicin Concentrations and Outcomes Following Maternal Once-Daily Gentamicin Dosing.

Wilson G, Bondi D, Shah P, Nelson A, Kumar M, Bhagat P J Pediatr Pharmacol Ther. 2023; 28(4):316-322.

PMID: 37795280 PMC: 10547053. DOI: 10.5863/1551-6776-28.4.316.


Management of clinical chorioamnionitis: an evidence-based approach.

Conde-Agudelo A, Romero R, Jung E, Garcia Sanchez A Am J Obstet Gynecol. 2020; 223(6):848-869.

PMID: 33007269 PMC: 8315154. DOI: 10.1016/j.ajog.2020.09.044.


Histologic chorioamnionitis and risk of neurodevelopmental impairment at age 10 years among extremely preterm infants born before 28 weeks of gestation.

Venkatesh K, Leviton A, Hecht J, Joseph R, Douglass L, Frazier J Am J Obstet Gynecol. 2020; 223(5):745.e1-745.e10.

PMID: 32387324 PMC: 7609587. DOI: 10.1016/j.ajog.2020.05.001.


Antibiotic regimens for management of intra-amniotic infection.

Chapman E, Reveiz L, Illanes E, Bonfill Cosp X Cochrane Database Syst Rev. 2014; (12):CD010976.

PMID: 25526426 PMC: 10562955. DOI: 10.1002/14651858.CD010976.pub2.